Delonix Bioworks Ltd., a Shangai, China-based biotechnology company dedicated to developing the next generation vaccines with synthetic biology approaches, closed a $14m seed financing.
The round was led by Boehringer Ingelheim Venture Fund (BIVF) and IDG Capital, with participation from ZhenFund and an undisclosed investor.
The company intends to use the funds to accelerate the building of synthetic biology vaccine platforms and advance pipelines of synthetic vaccines to clinical trials.
Led by Dr. Qiubin Lin, CEO, Delonix is a biotech company working on innovative synthetic biology approaches to develop the next generation medical solutions to address global public health challenges. Its synthetic biology and antigen discovery platforms enable rational design and programming of bacteria into more safe and effective vaccines. Current lead programs target anti-microbial resistance (AMR).